retatrutide glp-1 gip glucagon agonist Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor Agonism Differs From Existing Compounds Curious about the differences between

sounds dumb but its nice Karen D., 52, Montreal QC Weeks 25-36 Summary: Patience Pays Off Weight loss: 4-8 pounds this period (42-46 pounds total, ~21% of starting weight) Weekly loss rate: Averages 0.3-0.7 pounds weekly (significantly slower but still progressing) Body composition: Often improving more than scale suggests Discontinuation rate: 2-3% stop during this period, usually from frustration with slowing progress Psychological state: Requires intentional perspective maintenance Key achievement: Persisting through plateau without giving up or making counterproductive changes Weeks 37-48: The Plateau Phase (12mg Maintenance) Starting Weight Week 37: ~174 pounds | Expected Weight Week 48: 167-171 pounds | Net Loss This Period: 3-7 pounds | Total Loss: 49-53 pounds Whats Happening Physiologically Approaching maximum effect of Retatrutide at 12mg weekly dose

Improved Glycemic Control: GIP receptor activation enhances insulin sensitivity, while glucagon receptor activation promotes fat oxidation, making these agents effective for adolescents with both obesity and insulin resistance

Strong-smelling foods trigger the olfactory-nausea connection that makes hot foods problematic

Gene expression studies reveal exercise-like transcriptional signatures